Filing Flows › Health Care › Myomo (MYO)
Myomo (MYO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 5, 2026 · Myomo (MYO) Q2 2026 earnings results →
Q2 2026 Revenue up 21% year over year to $11.7M · 34¢ of every $1 of revenue lost · operating margin -19.3%
Myomo made $11.7M in Q2 2026 (+21% Y/Y). Operating margin -19.3%, net loss $4.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $11.7M in Q2 2026, up 21% year over year and up 16% from the previous quarter.
Gross margin was 72.1%, up 9.4 points from Q2 2025. Operating costs exceeded revenue by $2.3M, an operating margin of -19.3%. Operating expenses grew 1% against revenue growth of 21%. The quarter ended with a net loss of $4.0M, wider than the previous quarter's $3.0M loss.
Operating cash flow was −$1.9M. Non-cash charges added back $385K of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items added $650K. Capital expenditures of $32K exceeded it, leaving free cash flow of −$2.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 5, 2026 | $11.7M | +21% | -19.3% | −$4.0M | −$1.9M |
| Q1 2026 | 10-Q | May 7, 2026 | $10.1M | +3% | -31.2% | −$3.0M | −$2.2M |
| Q4 2025 | 10-K | Mar 9, 2026 | $11.4M | -6% | -24.4% | −$3.8M | −$1.1M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $10.1M | +10% | -34.9% | −$3.7M | −$1.8M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $9.7M | +28% | -47.6% | −$4.6M | −$8.9M |
| Q1 2025 | 10-Q | May 7, 2025 | $9.8M | +162% | -35.8% | −$3.5M | −$2.7M |
| Q4 2024 | 10-K | Mar 10, 2025 | $12.1M | +154% | -2.0% | −$260K | $3.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 54% of its revenue · Stated in 10-K (sentence) · source
About Myomo
We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs. Our products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders.
In its own words, from its 10-K, filed Mar 9, 2026.
Myomo against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +21% against the peers' median +10%. Operating margin: -19.3% against the peers' median 16.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MYO Myomo | Q2 2026 | $11.7M | +21% | -19.3% |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
Source: Myomo 10-Q on SEC EDGAR · CIK 1369290 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
13F: who owns MYO and who is buying
More on MYO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results